RHA Redensity - Perioral Rhytids
A Randomized, Blinded, No-Treatment Control, Multicenter, Prospective Clinical Study of TEOSYAL RHA® Redensity for the Treatment of Moderate to Severe Dynamic Perioral Rhytids
Sponsor: Teoxane SA
Listed as NCT03092219, this NA trial focuses on Aging and Perioral Rhytids and remains completed. Sponsored by Teoxane SA, it has been updated 12 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2023 — Jul 2024 [monthly]
Completed NA
-
Jan 2022 — Jul 2023 [monthly]
Completed NA
-
Jun 2021 — Jan 2022 [monthly]
Completed NA
▶ Show 7 earlier versions
-
May 2021 — Jun 2021 [monthly]
Completed NA
-
Jan 2021 — May 2021 [monthly]
Completed NA
-
Aug 2020 — Jan 2021 [monthly]
Completed NA
Status: Withheld → Completed · Phase: None → NA
-
Mar 2020 — Aug 2020 [monthly]
Withheld
-
Jun 2018 — Mar 2020 [monthly]
Withheld
-
Apr 2018 — Jun 2018 [monthly]
Withheld
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Withheld NA
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teoxane SA
For direct contact, visit the study record on ClinicalTrials.gov .